Peptide Database

Anti-Obesity Drug 9604 · hGH Fragment 177-191

AOD-9604 is a modified fragment of human growth hormone (hGH 177-191) that retains the lipolytic properties of GH without its anabolic or diabetogenic effects. It stimulates lipolysis through β3-adrenergic receptor pathways and inhibits lipogenesis. Phase 3 trials for obesity were conducted; it has since been investigated for osteoarthritis through cartilage repair properties.

Serelaxin · H2 relaxin

Relaxin-2 is an endogenous peptide hormone structurally related to insulin, primarily known for its role in pregnancy (cervical ripening, joint laxity). Research discovered its potent anti-fibrotic properties — it remodels collagen networks in heart, kidney, lung, and liver — making it a leading candidate for fibrosis and acute heart failure. Serelaxin (recombinant relaxin) reached Phase 3 trials for acute heart failure with promising early signals but did not meet primary endpoints.

LY3437943

Retatrutide is a triple agonist targeting GIP, GLP-1, and glucagon receptors simultaneously. Phase 2 trials demonstrated up to 24.2% body weight reduction — the highest achieved by any pharmacotherapy to date. The addition of glucagon agonism enhances energy expenditure and lipid metabolism beyond dual incretin agonists. Phase 3 trials are underway for obesity and NASH.